This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia 2009-10-28 14:05 ET - News Release
NEW YORK & BUDAPEST, Hungary -- (Business Wire)
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc today
announced positive top-line results from a Phase IIb clinical trial of
the novel, investigational antipsychotic agent cariprazine for the
treatment of acute exacerbation of schizophrenia.
For the primary endpoint, the Positive and Negative Syndrome Scale
(PANSS), the data showed that patients with schizophrenia treated with
cariprazine experienced significant symptom improvement compared to
placebo patients within the first week of treatment and at each
subsequent time point studied.
Based on this latest schizophrenia data, subject to a complete review of
the full results, and the previously announced Phase II results in
patients suffering from acute mania associated with bipolar I disorder,
the companies intend to initiate Phase 3 trials for both indications in
early 2010. Cariprazine is currently also undergoing Phase II clinical
trials in patients with Bipolar Depressive Disorder and as adjunctive
therapy in Major Depressive Disorder.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. | 
Top
Print this Page